The China question, FDA leadership shakeups, and other biotech news from The Readout

One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. | After an…

The China question, FDA leadership shakeups, and other biotech news from The Readout